More on ABBV
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $138.50 |
|
|||
| Open | $138.50 | ||||
| 52 Wk High | $68.12 | ||||
| 52 Wk Low | $50.71 | ||||
| Day High | $138.50 | ||||
| Day Low | $138.50 | ||||
| P/E | 30.04 | ||||
| EPS | $4.61 | ||||
| Volume | 206 | ||||
- AbbVie (ABBV) Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin for Patients with Previously Treated NSCLC
- AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
- AbbVie (ABBV) Reports FDA and EMA Updates for Epcoritamab
- AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
- Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever
- AbbVie (ABBV) Reports Publication Showing UBRELVY Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine
- Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine
- Form 25-NSE AbbVie Inc. Filed by: NEW YORK STOCK EXCHANGE LLC
- NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year
- Deutsche Bank Starts Abbvie (ABBV) at Hold
Entities mentioned with ABBV
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Dividend | View Related Stories »
- Morgan Stanley | View Related Stories »
- Options | View Related Stories »
- Goldman Sachs | View Related Stories »
- Show More...
